The ask comes days after Sarepta, which has a major presence in Columbus, announced it would lay off 500 workers, including 80 in central Ohio. The Food and Drug Administration announced the move, confirming an earlier Reuters report, after making the ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died,

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still walk. A pause on shipments to older, non-ambulatory patients remains in place.